Breaking News

Evotec, Debiopharm Enter Development Pact

April 2, 2014

To develop compounds for the potential treatment of cancer

Evotec AG has entered a research collaboration and licensing agreement with Debiopharm Group to identify and develop compounds for the potential treatment of multiple forms of solid tumors and leukemias, with defined genetic alterations.
 
Evotec will provide discovery and preclinical development services and Debiopharm will be responsible for clinical development. Evotec will receive R&D funding and payments based on clinical, regulatory and commercial milestones, as well as royalties on sales of resulting products.
 
Dr. Cord Dohrmann, chief scientific officer of Evotec, said, "We are very excited about this innovative collaboration. It combines our proven discovery platform with Debiopharm's ability to advance projects through clinical development in a highly efficient manner while sharing risks and rewards of Evotec's Target X project. There is compelling science around the target and we are confident that we will be able to position highly competitive compounds in this field that hold great potential for difficult to treat cancers."
 
"This is a fine example of how drug discovery and development will be in the future; a mixture of complementarities looking to bring to a defined population of patients a drug that will change the outcome of disease,” said Andres McAllister, chief scientific officer, Debiopharm International SA.

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent